Companies /Healthcare
Exelixis Inc
NASDAQ: EXEL Biotechnology
$70.13
▲ $0.74 (+1.07%) today
Markets closed · 3:43am ET

Exelixis (EXEL) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+13.58%
Avg. EPS surprise
Consecutive EPS beats
EXEL vs Market · 30-day return after each reportEXELS&P 500
−5%0%+5%+10%+2.6%+2.2%Q2 25+4.5%+0.9%Q3 25−4.4%−3.3%Q4 25+6.2%+0.7%Q1 26+10.5%−0.3%Q2 26
−5%0%+5%+10%Q2 25Q3 25Q4 25Q1 26Q2 26
EXEL EPS Trend · estimate vs actualEstimateActual
$0.00$0.30$0.60$0.90$0.65$0.75Q2 25$0.67$0.78Q3 25$0.75$0.94Q4 25$0.76$0.87Q1 26$0.86$0.91Q2 26$0.90$0.94Q3 26
$0.00$0.30$0.60$0.90Q2 25Q4 25Q2 26
EXEL Revenue Trend · estimate vs actualEstimateActual
$0$200.0M$400.0M$600.0M$579.5M$568.3MQ2 25$589.8M$597.8MQ3 25$601.1M$598.7MQ4 25$604.9M$610.8MQ1 26$636.2M$628.7MQ2 26$648.5M$658.7MQ3 26
$0$200.0M$400.0M$600.0MQ2 25Q4 25Q2 26

How Often Does Exelixis Beat Earnings Estimates?

Exelixis beat EPS estimates in 6 of its last 6 reported quarters, and has beaten 6 quarters in a row.

EXEL quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 $0.94 est. $0.90 +3.98% $658.7M est. $648.5M +1.57%
Q2 2026 $0.91 est. $0.86 +5.92% $628.7M est. $636.2M −1.17%
Q1 2026 $0.87 est. $0.76 +14.47% $610.8M est. $604.9M +0.98%
Q4 2025 $0.94 est. $0.75 +25.33% $598.7M est. $601.1M −0.40%
Q3 2025 $0.78 est. $0.67 +16.42% $597.8M est. $589.8M +1.36%
Q2 2025 $0.75 est. $0.65 +15.38% $568.3M est. $579.5M −1.93%

Figures from SEC filings and company reports. Not investment advice.